⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2393191 | 0.78 | SYK (0.31) | — | |
| SCHEMBL643186 | 0.70 | KDM4E (0.40) | — | |
| SCHEMBL6474878 | 0.69 | ESR1 (0.32) | — | |
| Hydrochloric Acid SCHEMBL4180932 | 0.69 | KDM4E (0.42) | — | |
| SCHEMBL508099 | 0.68 | TRPA1 (0.31) | — | |
| SCHEMBL2895204 | 0.68 | USP14 (0.31) | — | |
| SCHEMBL3662584 | 0.68 | HCAR3 (0.40) | — | |
| SCHEMBL508699 | 0.67 | CYP26A1 (0.31) | — | |
| SCHEMBL1997009 | 0.67 | CYP3A4 (0.33) | — | |
| SCHEMBL17111856 | 0.65 | RXRA (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9233969-B2 | Therapeutic agent for cerebral infarction | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-01-12 | — | — | US | disclosed |
| US-20150105400-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-04-16 | — | — | US | disclosed |
| US-20150104483-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-04-16 | — | — | US | disclosed |
| US-20140350249-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-11-27 | — | — | US | disclosed |
| US-20140350250-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-11-27 | — | — | US | disclosed |
| US-8835631-B2 | Therapeutic agent for cerebral infarction | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-09-16 | — | — | US | disclosed |
| EP-2154135-B1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-02-27 | — | — | EP | disclosed |
| EP-2532658-A1 | Therapeutic agent for cerebral infarction | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-12-12 | — | — | EP | disclosed |
| US-20100179157-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-07-15 | — | — | US | disclosed |
| EP-2154135-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-02-17 | — | — | EP | disclosed |